Review article: Treatment of Clostridium difficile infection

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 6, 1997, Pages 1003-1012

  Zimmerman, M J ^a   Bak, A ^a,b   Sutherland, L R ^c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; CLOSTRIDIUM DIFFICILE TOXIN A; FUSIDIC ACID; METRONIDAZOLE; PLACEBO; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; DATA BASE; DIARRHEA; FECES ANALYSIS; HUMAN; INTESTINE INFECTION; PRIORITY JOURNAL; RELAPSE;

EID: 0030833009     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00269.x     Document Type: Article

References (74)

1. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. J Am Med Assoc 1993; 269: 71-5.
2. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
3. Tabaqchali S, Jummaa P. Diagnosis and management of Clostridium difficile infection. Br Med J 1995: 310: 1375-80.
4. Finney JMT. Gastroenterology for cicratizing ulcer of the pylorus. Johns Hopkins Hosp Bull 1893; 4: 53-5.
5. Hall IC, O'Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935; 49: 390-402.
6. Tedesco FJ, Barton RW, Alpcrs DH. Clindamycin-associated colitis: A prospective study. Ann Intern Med 1974: 81: 429-33.
7. Bartlett JG, Chang TW, Gunwith M, Gorbach SL, Ondcrdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531-4.
8. George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br MedJ 1978; i: 695.
9. George WL, Sutler VL, Goldstein EJC, Ludwigh SL. Finegold SM. Aetiology of antimicrobial agent-associated colitis. Lancet 1978; i: 802-3.
10. Larson HE, Price AB, Honour P, Bordello SP. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978; i: 1063-6.
11. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomised controlled trials in health care from the Potsdam Consultation on Meta-analysis. J Clin Epidemiol 1995; 48: 167-71.
12. Dickersin K, Scherer R, LeFebvre C. Identifying relevant studies for systematic reviews. Br Med J 1995; 309: 1286-91.
13. REVMAN DOS version. The Cochrane Collaboration. Review Manager Software. Hamilton, Canada: The Canadian Cochrane Center, 1994.
14. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 1978; 2: 1667-9.
15. Mogg GAG, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic associated colitis. Br J Surg 1982; 69: 137-9.
16. Teasley DG, Gerding DM, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; ii: 1043-6.
17. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985; 89: 1038-5.
18. Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs. vancomycin therapy for Clostridium difficile-induced diarrhoea: a randomised double blind trial. Arch Intern Med 1986: 146; 1101-4.
19. Fekety R, Suva J, Kauffman C, Buggy B, Decry HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 15-19.
20. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36: 2192-6.
21. The Swedish CDAD Study Group. Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin: a dose finding study. Scand J Infect Dis 1994: 26: 309-16.
22. Wenisch C, Parschalk B. Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metroni-dazole and fusidic acid for the treatment of Clostridium difficileassociated diarrhea. Clin Infect Dis 1996; 22: 813-18.
23. Mogg GAG, Arabi Y, Youngs D. et al. Therapeutic trials of antibiotic-associated colitis. Scand J Infect Dis 1980; (Suppl. 22): 41-5.
24. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981-8.
25. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990; 88: 137-40.
26. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992: 117: 297-302.
27. Borhan-Manesh F, Balan S, Fudin J. Can bismuth subsalicylate (PEPTO-BISMOL) prevent development of Clostridium difficile diarrhoea. Gastroenterology 1993; 104 (4, Part 2): A672.
28. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta lactam associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-48.
29. Potts L, Lewis SJ, Barry R. Randomised double blind placebo controlled study of the ability of Saccharomyces boulardii to prevent antibiotic related diarrhoea. Gut 1996; 38 (Suppl. 1): A61.
30. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 1994; 271: 1913-18.
31. Tedesco FJ, Corless JK, Brownstein RE. Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. Gastroenterology 1982; 83: 1259-60.
32. Gebhard RL, Gerding DN, Olson MM. et al Clinical and endoscopic findings in patients early in the course of Clostridium difficile-associated pseudomembranous colitis. Am J Med 1985; 78: 45-8.
33. Seppala K, Hjelt L, Sipponen P. Colonoscopy in the diagnosis of antibiotic-associated colitis: a prospective study. Scand J Gastroenterol 1981; 16: 465-8.
34. George WL. Sutler VL, Citron D, Finegold SM. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979: 9: 214-19.
35. Peterson LR, Gerding DN. Antimicrobial agents in Clostridium difficile intestinal diseases. In: Rambaud J-C, Ducluzeau R, eds. Clostridium difficile et Pathologie Intestinale [Clostridium difficile-associated Intestinal Diseases]. Paris: Springer, 1990: 115-27.
36. Cronberg S, Castor B, Thoren A. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection 1984: 12: 276-9.
37. Daniels J, Pristas A. Successful treatment of Clostridium difficile colitis with ciprofloxacin. J Clin Gastroenterol 1992; 15: 176-7.
38. Lettau LA. Oral fluoroquinolone therapy in Clostridium difficile enterocolitis. J Am Med Assoc 1988; 260: 2216-7.
39. Loge RV. Oral fluoroquinolone therapy for Clostridium difficile enterocolitis. J Am Med Assoc 1989: 261: 2063-1.
40. Fekety R, O'Connor R, Suva J. Rifampicin and pseudomembranous colitis. Rev Infect Dis 1983; 5 (Suppl. 3): S524-7.
41. Ariano RE, ZhancI GG, Harding GK. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis. Can Med Assoc J 1990; 142: 1049-51.
42. Heerze LD, Keim MA, Talbot JA, Armstrong GD. Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis 1994; 169: 1291-6.
43. Tjellstrom B, Stenhammar L, Eriksson S, Magnusson KE. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 1993; 341: 701-2.
44. Leung DY, Kelly CP, Boguniewicz M. et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118 (4. Part 1): 633-7.
45. Warny M. Denie C, Delmee M, Lefebvre C. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 1995; 50: 36-9.
46. Salccdo J, Keates S, Pothoulakis C, et al. Intravenous gammaglobulin, a novel treatment for severe unresponsive Clostridium difficile colitis. Gastroenterology 1996; 104: A1007.
47. Kuratsuji T, Oikawa T, Fukumoto T, et al. Factor XIII deficiency in antibiotic-associated pseudomembranous colitis and its treatment with factor XIII concentrate. Haemostasis -1982; 11: 229-34.
48. Baruchel S, Delifer JC, Sigalet D, et ni. Pseudomembranous colitis in sickle cell disease responding to exchange transfusion. J Pediatr 1992; 121: 915-17.
49. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978; ii: 226-8.
50. Larson HE, Levi AJ, Bordello SP. Vancomycin for pseudomembranous colitis. Lancet 1978; ii: 48.
51. George WL, Volpicelli NA, Stiner DB, et al. Relapse of pseudomembranous colitis after vancomycin therapy. N Engl J Med 1979; 301: 414-15.
52. Batts DH, Martin D. Holmes R. Suva J, Fekety R. Treatment of antibiotic-associated Clostridium difficile diarrhoea with oral vancomycin. J Pediatr 1980; 97: 151-3.
53. Fekety R, Silva J, Armstrong J, et al. Treatment of antibiotic associated enterocolitis with vancomycin. Rev Infect Dis 1981; 3: 273-81.
54. Johnson TA, Tabbut BR, Page CO. Treatment of antibioticassociated pseudomembranous colitis with metronidazole. Am J Hosp Pharm 1981; 38: 1034-5.
55. Silva J, Batts DH, Fekety R, et al. Treatment of Clostridium difficile colitis and diarrhoea with vancomycin. Am J Med 1981: 71: 815-22.
56. Cherry RD, Portnoy D, Jabbari M, et al. Metronidazole: an alternate therapy for antibiotic-associated colitis. Gastroenterology 1982: 82 (5, Part 1): 849-51.
57. \Valters BAJ, Roberts R, Stafford R. Seneviratne E. Relapse of antibiotic-associated colitis: endogeneous persistence of Clostridium difficile after vancomycin treatment. Gut 1983; 24: 206-12.
58. Bartlett JG. Treatment of antibiotic associated pseudomembranous colitis. Rev Infect Dis 1984: 6 (Suppl. 1): 235-41.
59. Fekety R. Suva J, Buggy B, Decry G. Treatment of antibioticassociated colitis with vancomycin. J Antimicrob Chemother 1984; 14 (Suppl. 1): 97-102.
60. Pashby NL, Bolton RP, Sherriff RJ. Oral metronidazole in Clostridium difficile colitis. Br Med J 1979: 1: 1605-6.
61. Talbot RW. Walker RC, Beart RW Jr. Changing epidemiology, diagnosis and treatment of Clostridium difficile toxin associated colitis. Br J Surg 1986: 73: 457-60.
62. Baird DR. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother 1989; 23: 167-9.
63. de Lalla F, Privitera G. Rinaldi E. et al Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob Agents Chemother 1989; 33: 1125-7.
64. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DM. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 19821991. Infect Control Hosp Epidemiol 1994: 15: 371-81.
65. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, CT: Appleton-Lange, 1990: Chap. 9.
66. Cozart JC, Kalangi SS. Clench MH, et d. Clostridium difficile diarrhoea in patients with AIDS versus non-AIDS controls. Methods of treatment and clinical response to treatment. J Clin Gastroenterol 1993; 16: 192-4.
67. Lu SS, Schwartz JM, Simon DM. Brandt LJ. Clostridium difficileassociated diarrhoea in patients with HIV positivity and AIDS: A prospective controlled study. Am J Gastroenterol 1994; 89: 1226-9.
68. Hutin YJ, Molina JM, Casin I. et al. Risk factors for Clostridiumdijflcih-associaled diarrhoea at an AIDS ward. AIDS 1993; 7: 1441-7.
69. Cappell MS, Philogene C. Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infection: a study of seven consecutive patients admitted from 1986 to 1992 to a university teaching hospital. Am J Gastroenterol 1993: 88: 891-7.
70. Heard SR, Wren B, Barnett MJ, Thomas JM, Tabaqchali S. Clostridium difficile infection in patients with haematological malignant disease. Epidemiol Infect 1988; 100: 63-72.
71. Barany P, Stenvinkel P, Nord CE, Bergstrom J. Clostridium difficile infection-a poor prognostic sign in urémie patients? Clin Nephrol 1992; 38: 53-7.
72. Leung AC, Orange G, McLay A, Hendersen IS. Clostridium rf/flM/e-associated colitis in urémie patients. Clin Nephrol 1985; 24: 242-8.
73. Bond F, Payne G, Bordello SP. Usefulness of culture in the diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 1995: 14: 223-6.
74. Riley TV, Bowman RA, Golledge CL. Usefulness of culture in the diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 1995; 14: 1109-10.